Page 544 - The Case Lab Book
P. 544
SWOT ANALYSIS
Phissons: SWOT Analysis
Do Nothing
Phissons are in a position of strength they have invested £250 million and
are weeks away from the launch of proxydychromil which has received
approval in both the UK and US for sale.
Furthermore it is a drug that treats both primary forms of asthma.
Strengths Weaknesses
- Major co. in industry - Command and control structure
- Financial strength
